Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02429167
Other study ID # NHC-TBI-PoNS-RT001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2015
Est. completion date August 18, 2017

Study information

Verified date January 2020
Source Neurohabilitation Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if clinic and home training with a study device will improve a balance deficit. The study device is called Portable Neuromodulation Stimulator (PoNS). The study device will be placed on the tongue to deliver nerve stimulation. The study is testing if use of the study device in conjunction with physical therapy will improve balance and gait in patients suffering from a TBI. The effects of using the device and undergoing therapy will be measured using standardized tests of movement control, gait, headache and other TBI symptoms.


Recruitment information / eligibility

Status Completed
Enrollment 122
Est. completion date August 18, 2017
Est. primary completion date August 18, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male or female, 18-65 years of age

- Documentation on initial TBI (defined as closed-head, non-penetrating, blunt, whiplash, or explosive blast-induced brain injury) severity (at time of injury): Glasgow Coma Scale (GCS) score 9-15, with loss of consciousness < 24 hours, post-traumatic amnesia =7 days, or hospital admission = 7 days post TBI

- If female, subject is not pregnant, not lactating, has a negative pregnancy test prior to receipt of the PoNS™ device, and agrees to use contraception from screening to end of the study

- Balance disorder with SOT composite score at least 16 points below normal resulting from a mild/moderate TBI without any concomitant pathologies

- At least 1 year post injury

- Stable neurologic status

- Prior participation in a focused physical rehabilitation program for TBI and deemed by their treating clinician/themselves to have reached a plateau

- Able to walk continuously on a treadmill for 20 minutes, level grade and at any speed, with support if needed

- Access to a treadmill and commitment to utilize this for the at-home portion of the study

- Able to understand the study procedures and give informed consent

- Willing and able to adhere to the study schedule

- Willing to complete a neuropsychological evaluation prior to inclusion

Exclusion Criteria:

- Medical finding from screening history and physical examination that is clinically significant or would otherwise impact patient safety or data integrity

- Medical finding from prior neuroradiologic study or recent MRI that is significant or that would impact patient safety or data integrity

- Planned use or use of any investigational product, pharmaceutical or device within 30 days preceding receipt of the PoNS device and during the entire study

- Balance or gait deficits due to lower extremity injury or neurological condition other than TBI

- Penetrating brain injury, craniotomy or refractory subdural hematoma

- Oral health problems at the time of recruitment

- Oral surgery within 3 months of screening

- History of oral cancer

- Non-removable metal orthodontic devices that could interfere with PoNS use

- Presence of metallic implant or other MRI-incompatible device

- Blood pressure abnormalities considered clinically significant

- Use of Coumadin or other anticoagulant except aspirin in the last 6 months

- Untreated or undiagnosed diabetes

- Diabetic neuropathy

- Active or recent (within 1 year) treatment for any cancer, excluding basal cell carcinoma.

- Neurological disorders other than those attributed to the primary diagnosis (neurodegenerative diseases such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease or other dementia, Amyotrophic Lateral Sclerosis)

- History of epileptic or other seizure disorders

- Known ischemic heart disease and/or history or atrial or ventricular arrhythmias with or without syncope

- Any other untreated or unstable acute or chronic, clinically significant medical condition for which the subject is currently undergoing treatment that the study investigator deems unsuitable for inclusion

- Use of a lower extremity biomechanical prosthetic with the exception of a splint for foot drop

- Females who are pregnant, lactating, or planning to become pregnant during the study

- Chronic use of any potentially interfering medication, or use of any medication that would compromise the ability to function or perform the study activities

- Addition of and/or major change in type or dosage of any prescription medication within 3 months prior to receipt of the PoNS device

- Active alcoholism. The study investigator will have the right to exclude subject participation if the subject seems intoxicated at time of screening and/or during any study appointment.

- History of drug abuse will be assessed

- Recent history of smokeless tobacco use

- Any reason that may be a threat to health or safety

- Any finding in the neuropsychological evaluation that makes the subject unsuitable for inclusion

Study Design


Intervention

Device:
Cranial nerve non-invasive neuromodulation via PoNS device
The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
Sham PoNS device
The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.

Locations

Country Name City State
Canada The Montreal Neurofeedback Center Montreal Quebec
United States Orlando Health Orlando Florida
United States Oregon Health and Science University Center for Regenerative Medicine Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Neurohabilitation Corporation

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Frequency of falls Daily for 5 weeks
Other Frequency of headaches Frequency of headaches will be assessed using the headache disability index 5 weeks
Primary Response to treatment defined as an 8 point change in the Sensory Organization Test (SOT) from baseline The SOT is an objective, automated measure of sensory-motor integration that evaluates the functional contribution of the somatosensory, visual, and vestibular components of balance. A composite score is calculated and compared with a database normalized for age and height. 5 weeks after the start of the intervention
Secondary Increase in SOT score from pre-training SOT score at the end of 2 weeks in lab training Two weeks after start of the intervention
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1